Philip Morris Expands Zyn Nicotine Pouch Lineup, Adds More Pouches Per Can — Update
By Elias Schisgall
Philip Morris International is beefing up its lineup of Zyn nicotine pouches along with the number it offers in a single can.
The expansion is part of Philip Morris' push to scale up the brand following substantial manufacturing investments and a key regulatory win this summer.
The company's U.S. division said Wednesday that it is beginning to sell its flagship Zyn dry pouches in 1.5mg and 8mg strengths, adding to existing offerings at 3mg and 6mg. It is also launching Zyn Ultra, a pouch with a higher moisture content than the flagship product, at 9mg and 11mg.
Philip Morris also said that it will transition to having 20 pouches per can for its 3mg and 6mg products during the fourth quarter, up from the 15 pouches in a typical can.
"Together, these products recognize that preferences are not one-size-fits-all: Legal-age adults looking to switch from cigarettes or other nicotine products should be provided with options, including a range of different nicotine levels, flavor profiles, and formats," the company said.
The expansion comes less than three months after the Food and Drug Administration said Zyn could market itself as less harmful than traditional cigarettes using the statement: "Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis."
Zyn is the most popular brand in a growing market for oral nicotine pouches, and Philip Morris has seized on the category as a revenue driver in recent years. In July, the company opened a $1.2 billion manufacturing campus in Colorado to meet demand for the product.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
September 09, 2026 18:39 ET (22:39 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
